Arcus Biosciences, Inc. (RCUS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 37.9M Q4 '21: 383M Q1 '22: 391.5M Q2 '22: 409.1M Q3 '22: 432.6M Q4 '22: 112M Q1 '23: 119M Q2 '23: 121M Q3 '23: 120M Q4 '23: 117M Q1 '24: 237M Q2 '24: 247M Q3 '24: 263M Q4 '24: 258M Q1 '25: 141M Q2 '25: 262M Q3 '25: 240M Q4 '25: 247M Q1 '26: 236M Q2 '26: 117M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: -278.8M Q4 '21: 54M Q1 '22: 59.7M Q2 '22: 66.9M Q3 '22: 75M Q4 '22: -280M Q1 '23: -299M Q2 '23: -313M Q3 '23: -323M Q4 '23: -340M Q1 '24: -270M Q2 '24: -293M Q3 '24: -318M Q4 '24: -330M Q1 '25: -436M Q2 '25: -338M Q3 '25: -375M Q4 '25: -386M Q1 '26: -398M Q2 '26: -486M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: -278.4M Q4 '21: 53M Q1 '22: 57.6M Q2 '22: 66.6M Q3 '22: 79.5M Q4 '22: -267M Q1 '23: -279M Q2 '23: -287M Q3 '23: -293M Q4 '23: -307M Q1 '24: -231M Q2 '24: -249M Q3 '24: -270M Q4 '24: -283M Q1 '25: -391M Q2 '25: -298M Q3 '25: -341M Q4 '25: -353M Q1 '26: -369M Q2 '26: -460M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: -244.1M Q4 '21: -256M Q1 '22: 464.3M Q2 '22: 473.3M Q3 '22: 446.1M Q4 '22: 438M Q1 '23: -314M Q2 '23: -306M Q3 '23: -288M Q4 '23: -306M Q1 '24: -210M Q2 '24: -247M Q3 '24: -158M Q4 '24: -170M Q1 '25: -300M Q2 '25: -339M Q3 '25: -462M Q4 '25: -482M Q1 '26: -488M Q2 '26: -474M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: -263.2M Q4 '21: -282M Q1 '22: 439M Q2 '22: 453M Q3 '22: 431.6M Q4 '22: 432M Q1 '23: -320M Q2 '23: -316M Q3 '23: -306M Q4 '23: -330M Q1 '24: -235M Q2 '24: -267M Q3 '24: -169M Q4 '24: -176M Q1 '25: -303M Q2 '25: -342M Q3 '25: -464M Q4 '25: -484M Q1 '26: -489M Q2 '26: -475M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '19: 43.9M Q1 '20: 44.3M Q2 '20: 48.6M Q3 '20: 65.1M Q4 '20: 63.5M Q3 '21: 70.1M Q1 '22: 71.2M Q2 '22: 71.8M Q3 '22: 72.2M Q1 '23: 73M Q2 '23: 73.2M Q3 '23: 74.6M Q1 '24: 86.2M Q2 '24: 91.1M Q3 '24: 91.4M Q1 '25: 98.4M Q2 '25: 106.5M Q3 '25: 106.5M Q1 '26: 125.4M Q2 '26: 126.1M Q1 '20 Q4 '20 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -4.15 Q4 '21: 0.71 Q1 '22: 0.83 Q2 '22: 0.99 Q3 '22: 1.20 Q4 '22: -3.72 Q1 '23: -3.85 Q2 '23: -3.96 Q3 '23: -4.00 Q4 '23: -4.15 Q1 '24: -3.11 Q2 '24: -3.09 Q3 '24: -3.15 Q4 '24: -3.10 Q1 '25: -4.19 Q2 '25: -3.17 Q3 '25: -3.44 Q4 '25: -3.31 Q1 '26: -3.19 Q2 '26: -3.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.